CN111050769A - 用于胆管癌的治疗的fgfr2抑制剂 - Google Patents

用于胆管癌的治疗的fgfr2抑制剂 Download PDF

Info

Publication number
CN111050769A
CN111050769A CN201880050198.0A CN201880050198A CN111050769A CN 111050769 A CN111050769 A CN 111050769A CN 201880050198 A CN201880050198 A CN 201880050198A CN 111050769 A CN111050769 A CN 111050769A
Authority
CN
China
Prior art keywords
fgfr
patient
mutants
fgfr2
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880050198.0A
Other languages
English (en)
Chinese (zh)
Inventor
J.C.布索拉里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN111050769A publication Critical patent/CN111050769A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201880050198.0A 2017-06-02 2018-06-01 用于胆管癌的治疗的fgfr2抑制剂 Pending CN111050769A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17174295 2017-06-02
EP17174295.0 2017-06-02
EP18171315.7 2018-05-08
EP18171315 2018-05-08
PCT/EP2018/064523 WO2018220206A1 (en) 2017-06-02 2018-06-01 Fgfr2 inhibitors for the treatment of cholangiocarcinoma

Publications (1)

Publication Number Publication Date
CN111050769A true CN111050769A (zh) 2020-04-21

Family

ID=62555054

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880050198.0A Pending CN111050769A (zh) 2017-06-02 2018-06-01 用于胆管癌的治疗的fgfr2抑制剂

Country Status (16)

Country Link
US (2) US11707463B2 (https=)
EP (1) EP3634414A1 (https=)
JP (2) JP2020521794A (https=)
KR (1) KR20200010505A (https=)
CN (1) CN111050769A (https=)
AU (1) AU2018278271B2 (https=)
BR (1) BR112019025056A2 (https=)
CA (1) CA3064317A1 (https=)
IL (1) IL271058A (https=)
JO (1) JOP20190280A1 (https=)
MA (1) MA49248A (https=)
MX (1) MX2019014366A (https=)
MY (1) MY204203A (https=)
PH (1) PH12019502710A1 (https=)
UA (1) UA126478C2 (https=)
WO (1) WO2018220206A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021233037A1 (zh) * 2020-05-18 2021-11-25 山东第一医科大学(山东省医学科学院) 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
PH12021551949A1 (en) * 2019-02-12 2022-07-18 Janssen Pharmaceutica Nv Cancer treatment
AU2020253827B2 (en) * 2019-03-29 2026-01-08 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
JP2022534742A (ja) * 2019-05-28 2022-08-03 キューイーディー セラピューティクス，インコーポレイテッド 胆管癌を治療するための方法
TW202114665A (zh) * 2019-08-05 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種吡咯并六員雜環化合物在製備治療ｆｇｆｒ２基因變異的腫瘤的藥物中的用途
CN114945367A (zh) * 2020-01-17 2022-08-26 贝达医药公司 作为fgfr激酶抑制剂的哒嗪和1,2,4-三嗪衍生物
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
KR20250117064A (ko) 2024-01-26 2025-08-04 충북대학교 산학협력단 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903534A (zh) * 2007-03-23 2010-12-01 翻译基因组学研究院 诊断、分类和治疗子宫内膜癌和初癌的方法
US20130296326A1 (en) * 2012-05-07 2013-11-07 Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
US20150366866A1 (en) * 2013-01-18 2015-12-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
MX2007014782A (es) 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
EP4063516A1 (en) 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
AU2016341445B2 (en) 2015-10-23 2020-08-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903534A (zh) * 2007-03-23 2010-12-01 翻译基因组学研究院 诊断、分类和治疗子宫内膜癌和初癌的方法
US20130296326A1 (en) * 2012-05-07 2013-11-07 Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
US20150366866A1 (en) * 2013-01-18 2015-12-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAWN Q. CHONG等: "The landscape of targeted therapies for cholangiocarcinoma:current status and emerging targets", 《ONCOTARGET》 *
JEAN-CHARLES SORIA等: "safety and activity of the panfibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma(CCA)", 《JOURNAL OF CLINICAL ONCOLOGY》 *
SARA A. BYRON等: "The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors", 《NEOPLASIA》 *
YU WANG等: "Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein", 《CANCER LETTER》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021233037A1 (zh) * 2020-05-18 2021-11-25 山东第一医科大学(山东省医学科学院) 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法

Also Published As

Publication number Publication date
US20200138809A1 (en) 2020-05-07
IL271058A (en) 2020-01-30
EP3634414A1 (en) 2020-04-15
US20240016801A1 (en) 2024-01-18
MX2019014366A (es) 2020-07-27
AU2018278271A1 (en) 2019-12-05
JP2023113650A (ja) 2023-08-16
JP2020521794A (ja) 2020-07-27
JOP20190280A1 (ar) 2019-12-02
MA49248A (fr) 2020-04-15
PH12019502710A1 (en) 2020-06-08
BR112019025056A2 (pt) 2020-06-16
KR20200010505A (ko) 2020-01-30
US11707463B2 (en) 2023-07-25
US12350266B2 (en) 2025-07-08
CA3064317A1 (en) 2018-12-06
MY204203A (en) 2024-08-15
AU2018278271B2 (en) 2024-07-04
UA126478C2 (uk) 2022-10-12
WO2018220206A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
CN111050769A (zh) 用于胆管癌的治疗的fgfr2抑制剂
JP7668777B2 (ja) 癌治療
TWI798199B (zh) 癌症治療
CN113645975A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
JP2016540726A (ja) 遺伝子突然変異を特徴とする癌の予防又は治療におけるｔｏｒキナーゼ阻害剤
HK40029054A (en) Fgfr2 inhibitors for the treatment of cholangiocarcinoma
CN112739347A (zh) 胆管癌的治疗
HK40051490A (en) Treatment of cholangiocarcinoma
CN113645974A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
EA043608B1 (ru) Ингибиторы fgfr2 для лечения холангиокарциномы
HK40103983A (en) Cancer treatment
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40013982A (en) Cancer treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029054

Country of ref document: HK